July 30, 2015
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
At Sygnature Discovery, we deliver world-leading drug discovery solutions to accelerate your compound from idea to clinic.
Our leadership team brings diverse experience and insight, driving collaboration and innovation across drug discovery.
Explore careers at Sygnature Discovery and join a global team committed to science, collaboration, and integrity.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
At Sygnature Discovery, we deliver world-leading drug discovery solutions to accelerate your compound from idea to clinic.
Our leadership team brings diverse experience and insight, driving collaboration and innovation across drug discovery.
Explore careers at Sygnature Discovery and join a global team committed to science, collaboration, and integrity.
Hear directly from our industry thought‑leaders on the topics that matter in taking drugs from ideas to the clinic.
No posts found.
Peak Proteins has now fully integrated with Sygnature Discovery.
